ABSTRACT
O fortalecimento em Cuidados Paliativos (CP) na Atenção Primária à Saúde (APS) aumenta a qualidade do atendimento no fim de vida e possibilita redução de complicações por longas internações. O objetivo deste trabalho foi analisar dados sobre a mortalidade ocorrida em portadores de doenças crônicas avançadas não transmissíveis vinculados à Unidade Básica de Saúde Vila Floresta do Grupo Hospitalar Conceição (USVF-GHC) e verificar quantos destes seriam elegíveis aos CP. Trata-se de uma pesquisa de caráter transversal, descritiva e de abordagem quantitativa e retrospectiva. Os dados são provenientes de registros eletrônicos em saúde, do relatório de monitoramento gerencial, dos prontuários na USVF-GHC e da vigilância epidemiológica de Porto Alegre. Utilizou-se a escala Palliative Care Screening Tool (PCST) para critério de elegibilidade à CP. De um total de 155 pessoas que faleceram e moravam no território de atuação da USVF-GHC no ano de 2019, 55,2%(n=86) eram do sexo feminino, 54,2%(n=84) eram idosos com mais de 80 anos, 23,9%(n=37) tinham o tempo entre diagnóstico e óbito com mais de 5 anos, em 69,7%(n=108) dos casos o local de falecimento foi o hospital, 66,5%(n=103) não tinham prontuário, para 34,8%(n=54) foram as neoplasias as principais causas de óbito e 42,6%(n=66) foram considerados elegíveis aos CP segundo a PCST. Conclui-se que o perfil de pessoas com diagnóstico há mais de cinco anos da doença que resultou no óbito poderia ser observado com maior atenção pelas equipes da APS no que diz respeito aos CP, aumentando as buscas ativas e estabelecendo comunicação efetiva com os hospitais na transferência de cuidados.
Strengthening in Palliative Care (PC) in Primary Healthcare (PHC) increases the quality of care at the end of life and reduces complications from long hospitalizations. The objective of this work was to analyze data on mortality that occurred in patients with advanced chronic non-communicable diseases associated with the Vila Floresta Primary Healthcare Center of the Conceição Hospital Group (VFPHC-CHG) and to verify how many of these would be eligible to PC. It is a transverse, descriptive and quantitative and retrospective approach research. Data come from electronic health records, management monitoring report, VFPHC-CHG medical records and Porto Alegre Epidemiological Surveillance. The Palliative Care Screening Tool (PCST) scale for PC eligibility criterion. Out of a total of 155 people who died and lived in the VFPHC-CHG covered territory in 2019, 55.2% (n = 86) were female, 54.2% (n = 84) were elderly and more 80 years old, 23.9% (n = 37) had died within five years after diagnosis, in 69.7% (n = 108) of cases the place of death was the hospital, 66.5% (n = 103) had no medical record, were neoplasms the main causes of death in 34.8%(n = 54), and 42.6% (n = 66) were considered eligible for PC according to PCST. It is concluded that the profile of people with diagnosis for over five years of the disease that resulted in death could be observed more carefully by PHC teams regarding PC, increasing the search for those who are eligible and establishing effective communication with hospitals in care transfer.
ABSTRACT
INTRODUCTION: Paroxysmal nocturnal hemoglobinuria (PNH) is a rare acquired disease, arising from the mutation of clonal hematopoietic stem cells, with an estimated incidence of 1 to 5 cases per million individuals. In pregnant women, adequate information regarding the prevalence of PNH is lacking, and its management has been a challenge because of the significant complications in this group. The condition is diagnosed based on clinical findings and laboratory tests. Eculizumab, the drug of choice for the treatment of PNH, reduces hemolysis and stabilizes hemoglobin levels, thereby decreasing the need for blood transfusions and improving the overall quality of life. CASE PRESENTATION: A 38-year-old woman was diagnosed with PNH in 2007 and eculizumab therapy was initiated at the end of 2014. She became pregnant in September 2015 and presented various decompensations from forced reductions in therapy due to the nonavailability of eculizumab. The pregnancy was interrupted in week 35, but the well-being of the newborn was not compromised. The patient, however, had to remain hospitalized for resolution of acute kidney insufficiency, anemia, and intense hemolysis, which were reverted by means of intravenous hydration, transfusion of 10 packed red blood cell units, and eculizumab therapy. CONCLUSION: The rarity of the disease and the lack of protocols for its management during pregnancy hampered the treatment of the patient. However, the symptoms were progressively treated as they appeared, based on laboratory tests since it was necessary to circumvent and handle the lack of eculizumab which was not readily available in Brazil's Public Health System.
